Interesting facts
Interesting Facts about 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
This fascinating compound, known for its complex structure, features a unique isoxazole ring, which is a five-membered ring containing both nitrogen and oxygen. The incorporation of the trifluoromethyl group is particularly noteworthy, as it significantly influences the compound's properties.
Key Features
- Trifluoromethyl Substitution: The trifluoromethyl group (–CF3) not only enhances lipophilicity but also affects the electronic properties, making the compound an interesting candidate for medicinal chemistry.
- Biological Activity: Isoxazole derivatives have shown potential in various biological applications, including anti-inflammatory and anti-cancer activities, making this compound worth investigating in pharmaceuticals.
- Synthetic Versatility: The presence of multiple functional groups in the structure allows for diverse synthetic pathways, offering opportunities for structural modifications that can lead to new derivatives with enhanced efficacy.
Quote by a renowned chemist: "The beauty of organic chemistry lies in the imaginative transformations and the stories that each compound tells through its structure."
Research Implications
Researchers are intrigued by the potential applications of this compound in drug development. Its structural components may contribute to the creation of new therapeutic agents targeting specific diseases. The ability to modify the carboxamide group opens pathways for creating a library of compounds with varied biological profiles. Investigating the interactions of this compound with biological targets could lead to breakthroughs in treatment solutions.
In conclusion, 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide is a prime example of how intricate chemical structures can lead to promising research avenues in chemistry and medicinal science.
Synonyms
leflunomide
75706-12-6
Arava
Leflunomida
lefunamide
Leflunomidum
Repso
leflunomide medac
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
HWA 486
HWA-486
Leflunomidum [INN-Latin]
SU 101 (pharmaceutical)
SU101
Leflunomide teva
5-methyl-N-(4-(trifluoromethyl)phenyl)isoxazole-4-carboxamide
SU-101
Leflunomide winthrop
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
Leflunomida [INN-Spanish]
SULOL
Arava (TN)
Leflunomide ratiopharm
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
Arabloc
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
HSDB 7289
4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-
UNII-G162GK9U4W
NSC-677411
NSC-759864
CHEBI:6402
G162GK9U4W
5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
DTXSID9023201
L04AA13
MFCD00867593
N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
CHEMBL960
5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide)
MLS000069648
DTXCID103201
5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)-
Leflunomide [USAN:USP:INN:BAN]
NSC677411
NSC 677411
NSC 759864
NCGC00015610-02
SMR000058209
Leflunomide 100 microg/mL in Acetonitrile
CAS-75706-12-6
Leflunomidum (INN-Latin)
Leflunomida (INN-Spanish)
LEFLUNOMIDE (MART.)
LEFLUNOMIDE [MART.]
LEFLUNOMIDE (USP-RS)
LEFLUNOMIDE [USP-RS]
LEFLUNOMIDE (EP IMPURITY)
LEFLUNOMIDE [EP IMPURITY]
LEFLUNOMIDE (EP MONOGRAPH)
LEFLUNOMIDE [EP MONOGRAPH]
N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
LEFLUNOMIDE (USP MONOGRAPH)
LEFLUNOMIDE [USP MONOGRAPH]
Leflunomide (USAN:USP:INN:BAN)
N-(4-(TRIFLUOROMETHYL)PHENYL) 5 METHYLISOXAZOLE-4-CARBOXAMIDE
Lefunomide [Inn-Spanish]
Leflunomide [INN]
SR-01000000191
RS-34821
5-methyl-N-(4-(trifluoromethyl)phenyl)-1,2-oxazole-4-carboxamide
HWA486
N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
Prestwick_87
SU 101
5-methyl-N-
Leflunomide (Standard)
Spectrum_000322
LEFLUNOMIDE [MI]
Opera_ID_1709
Prestwick0_000772
Prestwick1_000772
Prestwick2_000772
Prestwick3_000772
Spectrum5_000850
LEFLUNOMIDE [JAN]
Lopac-L-5025
LEFLUNOMIDE [HSDB]
LEFLUNOMIDE [USAN]
L 5025
LEFLUNOMIDE [VANDF]
SCHEMBL5057
BIDD:PXR0189
Lopac0_000649
BSPBio_000844
KBioSS_000802
LEFLUNOMIDE [WHO-DD]
AP-501/42475599
Leflunomide, Immunosuppressant
MLS001076267
DivK1c_000916
Leflunomide (JAN/USP/INN)
SPECTRUM1503927
5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide
SPBio_002783
LEFLUNOMIDE [EMA EPAR]
BPBio1_000930
GTPL6825
Leflunomide - Bio-X trade mark
HMS502N18
HY-B0083R
KBio1_000916
KBio2_000802
KBio2_003370
KBio2_005938
LEFLUNOMIDE [ORANGE BOOK]
NINDS_000916
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl
HMS1570K06
HMS1922M06
HMS2090O12
HMS2097K06
HMS2235C07
HMS3262A19
HMS3268D12
HMS3371F21
HMS3414P03
HMS3654F07
HMS3673M17
HMS3678N21
HMS3714K06
HMS3865I13
Leflunomide for peak identification
Pharmakon1600-01503927
ALBB-019233
BCP22241
HY-B0083
PXB98723
Tox21_110182
Tox21_301873
Tox21_500649
BDBM50054601
DL-433
NSC759864
s1247
STL426823
AKOS000265193
Tox21_110182_1
AC-6796
BCP9000846
CCG-204736
CS-1781
DB01097
FL16204
KS-1076
LP00649
SB17287
SDCCGSBI-0050629.P003
IDI1_000916
NCGC00015610-01
NCGC00015610-03
NCGC00015610-04
NCGC00015610-05
NCGC00015610-06
NCGC00015610-07
NCGC00015610-08
NCGC00015610-09
NCGC00015610-10
NCGC00015610-11
NCGC00015610-12
NCGC00015610-13
NCGC00015610-14
NCGC00015610-17
NCGC00015610-18
NCGC00015610-30
NCGC00022625-03
NCGC00022625-04
NCGC00022625-05
NCGC00022625-06
NCGC00022625-07
NCGC00022625-08
NCGC00255370-01
NCGC00261334-01
BM164612
AB00052389
EU-0100649
L0250
NS00003822
SW196399-3
C07905
D00749
EN300-119495
MLS-0003109.0001
AB00052389-17
AB00052389-18
AB00052389_19
AB00052389_21
Q248550
SR-01000000191-2
SR-01000000191-4
SR-01000000191-7
BRD-K78692225-001-03-9
BRD-K78692225-001-11-2
BRD-K78692225-001-22-9
BRD-K78692225-001-23-7
BRD-K78692225-001-24-5
Z228668542
5-methyl-4-(4-trifluoromethyl-phenyl)aminocarbonylisoxazole
5-methyl-4-(4-trifluoromethylphenyl)aminocarbonylisoxazole
5-methylisoxazole-4-carboxylic acid trifluoromethylanilide
Leflunomide, European Pharmacopoeia (EP) Reference Standard
5-Methyl-N-[4-(trifluoromethyl)-phenyl]isoxazole-4-carboxamide
5-Methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4- carboxamide
5-Methyl-N-4-(trifluoromethyl)phenylisoxazole-4- carboxamide
5-methylisoxazole-4-carboxylic acid (4-trifluoromethyl)-anilide
N-(4-trifluoromethylphenyl)-5-methylisoxa-zole-4-carboxamide
Isoxazole-4-carboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-
Leflunomide, United States Pharmacopeia (USP) Reference Standard
HWA486; RS-34821; SU101;HWA 486; RS 34821; SU 101
Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material
Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard
Solubility of 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
The solubility characteristics of 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide (C12H9F3N2O2) are quite intriguing due to the unique combination of functional groups present in its structure. Solubility in solvents can be influenced by several factors:
Considering these aspects, the overall solubility profile can be summarized as follows:
Therefore, understanding the solubility of this compound is crucial for its application in various chemical processes and potential pharmaceutical formulations. As always, empirical testing remains essential for precise solubility data.